Carbapenem-resistant organisms

From IDWiki

Background

  • Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases

Management

Antibiotic KPC NDM OXA-48 CRPsA CRAB Stenotrophomonas
New antibiotics
aztreonam-avibactam + + + ± +
cefiderocol + + + + + +
ceftazidime-avibactam + + ±
ceftolozane-tazobactam ± ±
eravacycline + + + + +
imipenem-relebactam + ± +
meropenem-vaborbactam +
plazomicin + ± + ±
Old antibiotics
fosfomycin ± ± ± ±
colistin ± ± ± ± ± ±
tigecycline + + + + +
polymixins + + + + +
aztreonam ± ±
temocillin ±

Dosing

Antimicrobial Dose Targetted Organisms
amikacin 20 mg/kg IV load then per PK monitoring

Cystitis: 15 mg/kg IV once

ESBL-E, AmpC-E, CRE, DTR-PA
ampicillin-sulbactam 9 g IV q8h infused over 4 h, or 27 g IV over 24 hours continuous infusion CRAB
cefepime 2 g IV q8h infused over 2 h

Cystitis: 1 g IV q8h

AmpC-E
cefiderocol 2 g IV q8h infused over 3 h CRE, DTR-PA, CRAB, Stenotrophomonas
ceftazidime-avibactam 2.5 g IV q8h infused over 3 h CRE, DTR-PA
ceftazidime-avibactam plus aztreonam 2.5 g IV q8h infused over 3 h plus 2 g IV q8h infused over 3 h, infused concurrently if possible MBL CRE, Stenotrophomonas
ceftolozane-tazobactam 3 g IV q8h infused over 3 h

Cystitis: 1.5 g IV q8h infused over 1 h

DTR-PA
ciprofloxacin 400 mg IV q8-12h or 500-750 mg p.o. q12h ESBL-E, AmpC-E
colistin CRE cystitis, DTR-PA cystitis, CRAB cystitis
eravacycline 1 mg/kg IV q12h CRE, CRAB
ertapenem 1 g IV q24h infused over 30 min ESBL-E, AmpC-E
fosfomycin Cystitis: 3 g p.o. once ESBL-E. coli cystitis
gentamicin 7 mg/kg IV load then based on PK

Cystitis: 5 mg/kg IV once

ESBL-E, AmpC-, CRE, DTR-PA
imipenem-cilastatin ESBL-E or AmpC-E: 500 mg IV q6h infused over 30 min

CRE and CRAB: 500 mg IV q6h infused over 3 h Cystitis: 500 mg IV q6h infused over 30 min

ESBL-E, AmpC-E, CRE, CRAB
imipenem-cilastatin-relebactam 1.25 g IV q6h infused over 30 min CRE, DTR-PA
levofloxacin 750 mg p.o./IV q24h ESBL-E, AmpC-E, Stenotrophomonas
meropenem ESBL-E or AmpC-E: 1-2 g IV q8h infused over 30 min

CRE and CRAB: 2 g IV q8h infused over 30 min Cystitis: 1 g IV q8h, infused over 30 min

ESBL-E, AmpC-E, CRE, CRAB
meropenem-vaborbactam 4 g IV q8h infused over 3 h CRE
minocycline 200 mg IV/p.o. q12h CRAB, Stenotrophomonas
nitrofurantoin cystitis: macrocystals 100 mg p.o. q12h or oral suspension 50 mg p.o. q6h ESBL-E cystitis, AmpC-E cystitis
plazomicin 15 mg/kg IV load then dosed by PK

Cystitis: 15 mg/kg IV once

ESBL-E, AmpC-E, CRE, DTR-PA
polymyxin B DTR-PA, CRAB
tigecycline 200 mg IV load followed by 100 mg IV q12h CRE, CRAB, Stenotrophomonas
tobramycin 7 mg/kg IV load then dosed by PK

Cystitis: 5 mg/kg IV once

ESBL-E, AmpC-E, CRE, DTR-PA
co-trimoxazole 8-12 mg/kg/day (TMP) p.o./IV divided 18-12h

Cystitis: 160 mg (TMP) p.o./IV q12h

ESBL-E, AmpC-E, Stenotrophomonas

References

  1. ^  Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.